New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
06:20 EDTARAYAccuray buy thesis intact, but delayed, says Jefferies
Jefferies says Accuray's weaker than expected Q2 results and reduced FY13 outlook was not a surprise, but the severity of the downside was a surprise. The firm believes its Buy thesis on the stock remains intact, albeit delayed, and lowered its price target for shares to $6.50 from $10. Jefferies keeps a Buy rating on Accuray.
News For ARAY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 5, 2015
06:35 EDTARAYAccuray, RaySearch announce second long-term collaboration agreement
Accuray and RaySearch Laboratories announced that they have expanded on their existing relationship with the signing of a new long-term collaboration agreement which will lead to the integration of treatment planning support for the TomoTherapy and CyberKnife Systems in the RayStation treatment planning system, or TPS. RayStation is one of the most advanced independent treatment planning systems available and will provide an ideal complement to the unique Accuray treatment delivery systems, enabling customers to choose the delivery technology that will best meet their needs. Accuray and RaySearch previously announced a long-term collaboration regarding the RayCare oncology information system. Under the contract, Accuray will have the opportunity to offer RayStation to clinicians who use the TomoTherapy and CyberKnife System product portfolios. Current RayStation users report that the software provides multiple benefits including advanced treatment planning tools, leading workflow support, and an excellent user experience, all of which enhance treatment delivery flexibility within a radiation oncology department.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use